Friday, August 25, 2017

Home Dialysis Central "Heading Off The Dreaded Cramp!" by Dr. John Agar

http://homedialysis.org/news-and-research/blog/32-heading-off-the-dreaded-cramp

Heading Off The Dreaded Cramp!


This blog post was made by Dr. John Agar on August 24th, 2017.
Heading Off the Dreaded Cramp!
Cramp in patients with late stage chronic kidney disease (CKD5)—and on dialysis (CKD5d) when it is hard to get up and move around—is one of the worst symptoms of CKD5 and CKD5d. It is also one of the hardest to fully explain to patients, and to treat. We are not sure why some suffer more cramp than others. Despite how common and painful they are, the cause of cramp is poorly understood and under-researched...the latter, a real shame.
In CKD5d, cramp is most often found with a high ultrafiltration rate, and towards the end of a dialysis run. But, this is not always the case, as patients with a low UFR may also sometimes cramp.
In the dialysis patient, cramp tends to occur or to be worse late in a run. It tends to parallel the magnitude of change—in speed or degree—of change to the blood volume. Change to the inter-compartmental balance of salts like sodium, potassium, magnesium and calcium (electrolytes) is also a factor. Any acute change to blood volume and/or levels of electrolytes will also change extracellular and intracellular fluid volumes and electrolyte levels. The more abrupt or brief a treatment, the greater the risk of trans-compartmental electrolyte imbalance, and altered homeostasis.
An intra-dialytic change in the concentration of key electrolytes will result from:
  1. Losses or gains across the dialyzer membrane
  2. Fluid movement between the four major fluid spaces: intra-cellular, extra-cellular, intra-vascular and within-dialyser
Changes to stable homeostasis in dialysis within or between these four "compartments" is the key factor in provoking cramp. The more 'brutal' the treatment, the faster it is, the more likely that cramp will occur.
Why, then, do some patients also have cramps in bed at night, when noton dialysis?
The certain answer is unknown. But, we may forget that major shifts in blood volume occur as a function of normal physiology when moving from standing to lying down, then back to standing. It is a well-known fact that, upon lying down, adult blood volume expands at the expense of the extra-vascular fluid volume by a mean 600-700 ml in a 70 kg man (or ~10 ml/kgm).i
This fluid shift reverses upon standing up. The blood volume contracts back by the same amount, as fluid shifts back to the extravascular compartment.
These erect-to-supine-to-erect changes in blood volume take just a few minutes. As fluid moves back and forth between compartments, levels of common salts also change, depending on the direction of movement. As fluid moves into a compartment, the electrolyte levels in that compartment will fall. As fluid moves out, the electrolytes become more concentrated. This dilution/concentration phenomenon, based on fluid movement, also affects albumin. This is important as, though not an electrolyte, albumin plays a key part in fluid mechanics. For example, serum albumin is ~8% lower when lying supine than when standing, as it has been diluted by movement of fluid from the intravascular to the extracellular compartment.
These changing salt (electrolyte) and albumin levels affect electrical conductivity—the impulse a nerve fibre uses to stimulate a muscle cell...and, as you will see below, the stage is set for posture-related symptoms to result.
All of this happens in the setting of both CKD5 and CKD5d – and, in the case of CKD5d, homeostasis is already under an added threat from the dialysis treatment itself. In either case, a change in posture may magnify any pre-existing tissue electrolyte disturbance, and harm neuromuscular function. Holding that thought, let us turn to nerve and muscle function.
The junction between each microscopic nerve fibre and the single muscle cell fibre it supplies is known the "motor end plate". Here, the nerve ending touches the muscle cell fibre, just like the wiring of a house touches the back of a toaster plug to bring it power. When messaged from the brain, the nerve 'fires' the muscle cell, causing it to contract. The electrical signal to the nerve ending releases a slew of chemicals—neurotransmitters (or nerve-to-muscle stimulators)—from the nerve ending that then trigger muscle cell contraction.
Neurotransmitters depend on a stable mix of electrolytes in the fluid "soup" that bathes and surrounds the neuromuscular junction. The neurotransmitters and the electrolyte bath they work in, form a chemical "switch" that lets each nerve ending "talk" to its muscle cell. While there are conflicting data on the relative importance of each electrolyte, that they matter—and matter a lot—is not disputed.
Dialysis disturbs the balance between the electrolyte levels in the blood and tissue fluid. The effect is larger if the treatment is done quickly. The motor end plates become "super-trigger-happy"! While clearly a gross over-simplification, this results in the motor end plates firing off in an uncoordinated way. Muscle cells contract even when the brain has notsent a message. This unplanned muscle contraction leads to cramp.
Lots of treatments for dialysis cramp have been tried, with mixed success. Clearly the key step is to slow down the dialysis, so there is more time for electrolyte "equilibration" (= re-balance). This is the key reason why patients using slower, longer, extended-hour and higher frequency regimens (like frequent nocturnal dialysis) do not cramp. Those who use more frequent but shorter-time dialysis (eg: short daily dialysis) are not as well cramp-protected. Twice the frequency but half the time = an unaltered rate of fluid removal and homeostatic disturbance.
Taking extra salt is also not a good idea, it simply drives up blood pressure and activates thirst. Thirst causes a greater weight gain and the need to dial a higher UFR the next time round. This leads to greater, not lesser, chemical shifts and more, not less, cramp.
We use here—with good effect—an anti-epileptic drug (clonazepam). In our experience it works best of all. Other drugs and supplements have been tried, but with questionable value, including:
  • Vit E
  • Biotin
  • Leptin
  • L-carnitine
Evidence is not convincing that these are useful. Codeine can help some patients. Others get some relief from magnesium or quinine sulphate, though the latter carries the risk of platelet abnormalities and has dropped from favour.
But, the best treatment of all is to:
  1. Slow the ultrafiltration rate to allow within-dialysis fluid and electrolyte equilibration and eliminating the need for saline resuscitation during dialysis.
  2. Lessen post-dialysis thirst by avoiding acute volume contraction and reducing, not increasing, oral salt intake.
  3. By ensuring both (1) and (2), thereby avoiding the next large fluid gain/volume contraction cycle.
Above all, dialysis cramp is best remedied by longer slower dialysis, and not by taking the patient off early!

References

  1. Young DS, Bermes EW. Specimen collection and processing: Sources of biological variation. In: BurtisCA, AshwoodER eds. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, PA: WB Saunders and Company; 1999:79–81.

Thursday, August 17, 2017

NN&I Article on KIDNEY TRANSPLANT Study: Treatment with enzyme from bacteria reduces antibodies in kidney transplant recipients

Study: Treatment with enzyme from bacteria reduces antibodies in kidney transplant recipients


An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.
The study, published in the New England Journal of Medicine, found that treating patients with the drug IdeS before transplantation significantly reduced, and in most cases eliminated, donor-specific antibodies that can cause rejection or failure of the new organ.
IdeS is derived from an enzyme in the bacteria Streptococcus pyogenes, which causes disorders ranging from sore throats to life-threatening infections.
Stanley C. Jordan, MD, medical director of the Kidney Transplant Program at Cedars-Sinai, said the enzyme is the only one that can completely remove organ-rejecting antibodies and allow kidney transplantation to take place.  One hour after infusion of the enzyme, antibodies declined drastically.
“We found that IdeS could immediately cut patient antibodies in half, making them powerless to attack and injure a newly transplanted kidney,” said Jordan, who received a consulting fee from Hansa Medical of Sweden, the company that produced the enzyme and funded the research. “We can put a new kidney in a patient without it being rejected.”
The study involved two coordinated investigations, with a total of 25 patients treated in the U.S. and Sweden. Twenty-four of the patients were transplanted successfully after receiving the investigational therapy.
“We need larger studies to confirm the promising results of this unique approach to removing patient antibodies that threaten newly transplanted organs,” Jordan said. “And we want to investigate any long-term impact IdeS therapy may have on overall antibody production in patients.”

NN&I Article on Hand Hygiene Compliance

Hand hygiene compliance improves when patients are empowered to speak up



Armed with new tools to help them, patients and parents felt empowered to remind health care providers to perform hand hygiene, successfully improving compliance rates, according to a new study published in the August issue of the American Journal of Infection Control. But less than 60% of health care providers surveyed felt that patients should be involved in reminding providers to perform hand hygiene.
Allison Lastinger, MD, of the West Virginia University (WVU) School of Medicine, led a multidisciplinary research team that performed a cross-sectional survey of parents of hospitalized children, adult patients, and primary care physicians at the WVU Medicine J.W. Ruby Memorial Hospital, a 645-bed tertiary care teaching hospital in Morgantown, W.V.
Patients and their families were given one of the five patient empowerment tools (PETs, pictured) upon admission to the hospital and asked to use the tools to remind health care workers to perform hand hygiene.
Allison Lastinger, MD, holds a collection of patient empowerment tools, which are used by patients to remind nurses and doctors to wash their hands when entering their room.
Allison Lastinger, MD, holds a collection of patient empowerment tools, which are used by patients to remind nurses and doctors to wash their hands when entering their room.
Using an anonymous, self-administered questionnaire, the multidisciplinary research team— which included Kayeromi Gomez, PhD, of the WVU School of Public Health, Ellen Manegold, BA, of the WVU Department of Psychology, and Rashida Khakoo, MD, of the WVU School of Medicine — examined their attitudes toward the new patient empowerment tool at the hospital. The parent and patient surveys were distributed from December 2015 to June 2016; the physician survey was distributed in November 2015.
“Patient involvement is increasingly recognized as an important component of hand hygiene improvement strategies,” said Linda Greene, RN, MPS, CIC, FAPIC, 2017 president of the Association for Professionals in Infection Control and Epidemiology. “Organizations must realize that patients and families are an important part of the health care team, and their involvement in hand hygiene campaigns should be encouraged.”
A total of 222 adult patients and parents completed the survey (108 adult patients and 114 parents). Most adult patients (64%) and parents (70%) said the PET made them feel more in control of their care. Most parents (77% for physicians and 81.4 % for nurses) and adult patients (64.8% for physicians and 71.2% for nurses) felt comfortable using the PET to remind health care workers to perform hand hygiene.
Researchers noted, however, that parents were nearly 20% more likely than adult patients to speak up if a physician did not perform hand hygiene. In Ruby Memorial Hospital, hand hygiene rates increased from 48% in 2015 to approximately 75% in 2016 as a result of the hospital’s multipronged initiative to increase handwashing rates among its healthc are providers. “Forty-eight percent is pretty standard,” said lead study author Dr. Lastinger, “so 75 percent is phenomenal.”
Among 89 health care provider responses (29 residents and 60 attending physicians), only 54.9% felt that patients should be involved in reminding providers to perform hand hygiene. Overall, physicians indicated that they would prefer a patient make the request verbally, rather than using the PET to remind them to perform hand hygiene.
Of the physicians who did not support patient involvement, 37%f elt that it was not the patient’s responsibility to remind physicians to perform hand hygiene; 16% felt that it was embarrassing to the doctor; and 13% felt that it would have a negative impact on the patient-physician relationship.
“Based on the results of this study, patient empowerment appears to be an effective strategy to facilitate health care workers’ adherence to hand hygiene, but acceptance of the PET by providers remains a challenge,” said Lastinger. “Barriers to hand hygiene adherence among health care providers should be identified and addressed.”

Science Daily Article - Breakthrough device heals organs with a single touch

Breakthrough device heals organs with a single touch

Device instantly delivers new DNA or RNA into living skin cells to change their function

Date:
August 7, 2017
Source:
Ohio State University Wexner Medical Center
Summary:
Researchers have developed a device that can switch cell function to rescue failing body functions with a single touch. The technology, known as Tissue Nanotransfection (TNT), injects genetic code into skin cells, turning those skin cells into other types of cells required for treating diseased conditions.
Share:
     
FULL STORY

Researchers demonstrate a process known as tissue nanotransfection at The Ohio State University Wexner Medical Center. In laboratory tests, this process was able to heal the badly injured legs of mice in just three weeks with a single touch of this chip. The technology works by converting normal skin cells into vascular cells, which helped heal the wounds.
Credit: Courtesy The Ohio State University Wexner Medical Center
Researchers at The Ohio State University Wexner Medical Center and Ohio State's College of Engineering have developed a new technology, Tissue Nanotransfection (TNT), that can generate any cell type of interest for treatment within the patient's own body. This technology may be used to repair injured tissue or restore function of aging tissue, including organs, blood vessels and nerve cells.
Results of the regenerative medicine study published in the journal Nature Nanotechnology.
"By using our novel nanochip technology, injured or compromised organs can be replaced. We have shown that skin is a fertile land where we can grow the elements of any organ that is declining," said Dr. Chandan Sen, director of Ohio State's Center for Regenerative Medicine & Cell Based Therapies, who co-led the study with L. James Lee, professor of chemical and biomolecular engineering with Ohio State's College of Engineering in collaboration with Ohio State's Nanoscale Science and Engineering Center.
Researchers studied mice and pigs in these experiments. In the study, researchers were able to reprogram skin cells to become vascular cells in badly injured legs that lacked blood flow. Within one week, active blood vessels appeared in the injured leg, and by the second week, the leg was saved. In lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.
"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time. With this technology, we can convert skin cells into elements of any organ with just one touch. This process only takes less than a second and is non-invasive, and then you're off. The chip does not stay with you, and the reprogramming of the cell starts. Our technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary," said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.
TNT technology has two major components: First is a nanotechnology-based chip designed to deliver cargo to adult cells in the live body. Second is the design of specific biological cargo for cell conversion. This cargo, when delivered using the chip, converts an adult cell from one type to another, said first author Daniel Gallego-Perez, an assistant professor of biomedical engineering and general surgery who also was a postdoctoral researcher in both Sen's and Lee's laboratories.
TNT doesn't require any laboratory-based procedures and may be implemented at the point of care. The procedure is also non-invasive. The cargo is delivered by zapping the device with a small electrical charge that's barely felt by the patient.
"The concept is very simple," Lee said. "As a matter of fact, we were even surprised how it worked so well. In my lab, we have ongoing research trying to understand the mechanism and do even better. So, this is the beginning, more to come."
Researchers plan to start clinical trials next year to test this technology in humans, Sen said.
Funding for this research was provided by Leslie and Abigail Wexner, Ohio State's Center for Regenerative Medicine and Cell-Based Therapies and Ohio State's Nanoscale Science and Engineering Center.

Story Source:
Materials provided by Ohio State University Wexner Medical CenterNote: Content may be edited for style and length.

Journal Reference:
  1. Daniel Gallego-Perez, Durba Pal, Subhadip Ghatak, Veysi Malkoc, Natalia Higuita-Castro, Surya Gnyawali, Lingqian Chang, Wei-Ching Liao, Junfeng Shi, Mithun Sinha, Kanhaiya Singh, Erin Steen, Alec Sunyecz, Richard Stewart, Jordan Moore, Thomas Ziebro, Robert G. Northcutt, Michael Homsy, Paul Bertani, Wu Lu, Sashwati Roy, Savita Khanna, Cameron Rink, Vishnu Baba Sundaresan, Jose J. Otero, L. James Lee, Chandan K. Sen. Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescueNature Nanotechnology, 2017; DOI: 10.1038/nnano.2017.134

NN&I Article As kidney function decreases, risk for AFib increases

As kidney function decreases, risk for AFib increases


A new study published in the Clinical Journal of the American Society of Nephrology indicates that individuals with kidney disease have a higher risk of developing atrial fibrillation, or an irregular heartbeat.
Nisha Bansal, MD, MAS from the University of Washington, and her colleagues analyzed the results of three prospective studies: the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study.
In the analysis of 16,769 community-dwelling individuals without atrial fibrillation, there was a step-wise increase in the risk of incident atrial fibrillation with decreasing kidney function. In patients with the lowest kidney function or the greatest amount of proteinuria, the risk for developing atrial fibrillation was approximately two-fold higher compared with those without kidney disease.
This link held even after accounting for a wide range of possible contributors, including measures of cardiovascular health, and it was consistent across subgroups of participants categorized by age, sex, race, and comorbidity.
“This study found that even modest abnormalities in kidney function were linked with a higher risk of developing atrial fibrillation later in life,” said Bansal. “Atrial fibrillation may affect the selection of cardiovascular therapies and is associated with poor clinical outcomes. Thus, an understanding of the risk of atrial fibrillation across a broad range of kidney function is important.”
Dr. Bansal noted that additional studies are needed to determine the mechanistic link between kidney disease and atrial fibrillation.
Study co-authors include Leila Zelnick, PhD, Alvaro Alonso, MD, Emelia Benjamin, MD, ScM, Ian de Boer, MD, MS Rajat Deo, MD, Ronit Katz, DPhil, Bryan Kestenbaum, MD, MS, Jehu Mathew, MD, Cassianne Robinson-Cohen, PhD, Mark Sarnak, MD, MS, Michael Shlipak, MD, MPH, Nona Sotoodehnia, MD, MPH, Bessie Young, MD, MPH, and Susan Heckbert, MD, PhD.

Wednesday, August 9, 2017

Ohio State University Regenerative Medicine BREAKTHROUGH!!



Regenerative Medicine Breakthrough

TNT_research_blog_largeWe are ready to revolutionize regenerative medicine with our latest research finding: a new technology called Tissue Nanotransfection (TNT) that can generate any cell type of interest for treatment within the patient’s own body. This technology may be used to repair injured tissue or restore function of aging tissue, including organs, blood vessels and nerve cells.
Our study shows that injured or compromised organs can be replaced by using our novel nanochip technology. 
We have successfully shown that skin can be a fertile land where we can grow any cell type for a failing organ. 
As director of Ohio State’s Center for Regenerative Medicine & Cell Based Therapies, I co-led the study in collaboration with Ohio State’s Nanoscale Science and Engineering Center in the College of Engineering. Results of the regenerative medicine study are now published in the journal Nature Nanotechnology. 
Our teams studied mice and pigs in these experiments, and we were able to reprogram skin cells to become vascular cells in badly injured legs that lacked blood flow. Within one week, active blood vessels appeared in the injured leg, and by the second week, the injury was saved. In lab tests, this technology was also shown to reprogram skin cells in the live body into nerve cells that were injected into brain-injured mice to help them recover from stroke.
This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time. With this technology, we can convert skin cells into elements of any organ with just one touch. This non-invasive process only takes less than a second. The chip does not stay with you, and the reprogramming of the cell starts.
TNT technology has two major components: First is a nanotechnology-based chip designed to deliver cargo to adult cells in the live body. Second is the design of specific biological cargo for cell conversion. This cargo, when delivered using the chip, converts an adult cell from one type to another. The cargo is delivered by zapping the device with a small electrical charge that’s barely felt by the patient.
We plan to start clinical trials next year to test this technology in humans, where we are hopeful for continued success.


Researchers at The Ohio State University Wexner Medical Center and College of Engineering are ready to revolutionize regenerative medicine with their latest research finding: a new technology called Tissue Nanotransfection (TNT) that can generate any cell type of interest for treatment within the patient’s own body. This technology may be used to repair injured tissue or restore function of aging tissue, including organs, blood vessels and nerve cells.